Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 14-12-2023 | Metastasis | Original Article

The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation

Authors: Riccardo Mei, Thomas Pyka, Hasan Sari, Stefano Fanti, Ali Afshar-Oromieh, Roland Giger, Federico Caobelli, Axel Rominger, Ian Alberts

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2024

Abstract

Purpose

To evaluate the utility of long duration (10 min) acquisitions compared to standard 4 min scans in the evaluation of head and neck cancer (HNC) using a long-axial field-of-view (LAFOV) system in 2-[18F]FDG PET/CT.

Methods

HNC patients undergoing LAFOV PET/CT were included retrospectively according to a predefined sample size calculation. For each acquisition, FDG avid lymph nodes (LN) which were highly probable or equivocal for malignancy were identified by two board certified nuclear medicine physicians in consensus. The aim of this study was to establish the clinical acceptability of short-duration (4 min, C_40%) acquisitions compared to full-count (10 min, C_100%) in terms of the detection of LN metastases in HNC. Secondary endpoints were the positive predictive value for LN status (PPV) and comparison of SUV_max at C_40% and C_100%. Histology reports or confirmatory imaging were the reference standard.

Results

A total of 1218 records were screened and target recruitment was met with n = 64 HNC patients undergoing LAFOV. Median age was 65 years (IQR: 59–73). At C_40%, a total of 387 lesions were detected (highly probable LN n = 274 and equivocal n = 113. The total number of lesions detected at C_100% acquisition was 439, of them 291 (66%) highly probable LN and 148 (34%) equivocal. Detection rate between the two acquisitions did not demonstrate any significant differences (Pearson’s Chi-Square test, p = 0.792). Sensitivity, specificity, PPV, NPV and accuracy for C_40% were 83%, 44%, 55%, 76% and 36%, whilst for C_100% were 85%, 56%, 55%, 85% and 43%, respectively. The improved accuracy reached borderline significance (p = 0.057). At the ROC analysis, lower SUVmax was identified for C_100% (3.5) compared to C_40% (4.5).

Conclusion

In terms of LN detection, C_40% acquisitions showed no significant difference compared to the C_100% acquisitions. There was some improvement for lesions detection at C_100%, with a small increment in accuracy reaching borderline significance, suggestive that the higher sensitivity afforded by LAFOV might translate to improved clinical performance in some patients.

Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776–81.CrossRefPubMed

Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1988;29:1521.PubMed

Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2020;18:873–98. https://doi.org/10.6004/jnccn.2020.0031.CrossRefPubMed

Surti S, Viswanath V, Daube-Witherspoom ME, Conti M, Casey ME, Karp JS. Benefit of improved performance with state-of-the art digital PET/CT for lesion detection in oncology. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.242305.

Alberts I, Hünermund J-N, Sachpekidis C, Mingels C, Fech V, Bohn KP, et al. The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. Eur Radiol. 2021. https://doi.org/10.1007/s00330-021-07870-5.CrossRefPubMedPubMedCentral

Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47:614–23. https://doi.org/10.1007/s00259-019-04630-y.CrossRefPubMed

Lopez-Mora DA, Flotats A, Fuentes-Ocampo F, Camacho V, Fernandez A, Ruiz A, et al. Comparison of image quality and lesion detection between digital and analog PET/CT. Eur J Nucl Med Mol Imaging. 2019;46:1383–90. https://doi.org/10.1007/s00259-019-4260-z.CrossRefPubMed

Alberts I, Hünermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05282-7.CrossRefPubMedPubMedCentral

Leung EK, Berg E, Omidvari N, Spencer BA, Li E, Abdelhafez YG, et al. Quantitative accuracy in total-body imaging using the uEXPLORER PET/CT scanner. Phys Med Biol. 2021;66. https://doi.org/10.1088/1361-6560/ac287c.

10.

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60:299–303. https://doi.org/10.2967/jnumed.119.226498.CrossRefPubMedPubMedCentral

11.

Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59:3–12. https://doi.org/10.2967/jnumed.116.184028.CrossRefPubMedPubMedCentral

12.

Karp JS, Viswanath V, Geagan MJ, Muehllehner G, Pantel AR, Parma MJ, et al. PennPET explorer: design and preliminary performance of a whole-body imager. J Nucl Med. 2020;61:136–43. https://doi.org/10.2967/jnumed.119.229997.CrossRefPubMedPubMedCentral

13.

Vandenberghe S, Moskal P, Karp JS. State of the art in total body PET. EJNMMI Phys. 2020;7:35. https://doi.org/10.1186/s40658-020-00290-2.CrossRefPubMedPubMedCentral

14.

Prenosil GA, Weitzel T, Furstner M, Hentschel M, Krause T, Cumming P, et al. Towards guidelines to harmonize textural features in PET: Haralick textural features vary with image noise, but exposure-invariant domains enable comparable PET radiomics. PLoS ONE. 2020;15:e0229560. https://doi.org/10.1371/journal.pone.0229560.CrossRefPubMedPubMedCentral

15.

Fu F, Li X, Wu Y, Xu J, Bai Y, Gao Y, et al. Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2021;48:1678–9. https://doi.org/10.1007/s00259-020-05121-1.CrossRefPubMed

16.

Price PM, Badawi RD, Cherry SR, Jones T. Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning. J Nucl Med. 2014;55:696–7. https://doi.org/10.2967/jnumed.113.133892.CrossRefPubMed

17.

Sachpekidis C, Pan L, Kopp-Schneider A, Weru V, Hassel JC, Dimitrakopoulou-Strauss A. Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-06070-7.CrossRefPubMedPubMedCentral

18.

Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR, et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med. 2009;50:1205–13. https://doi.org/10.2967/jnumed.109.062075.CrossRefPubMed

19.

Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Coleman RE. Head and neck cancer: dedicated FDG PET/CT protocol for detection–phantom and initial clinical studies. Radiology. 2007;244:263–72. https://doi.org/10.1148/radiol.2433060043.CrossRefPubMed

20.

Ciappuccini R, Aide N, Blanchard D, Rame J-P, de Raucourt D, Michels J-J, et al. Incremental value of a dedicated head and neck acquisition during 18F-FDG PET/CT in patients with differentiated thyroid cancer. PLoS ONE. 2016;11:e0162482. https://doi.org/10.1371/journal.pone.0162482.CrossRefPubMedPubMedCentral

21.

Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. AJR Am J Roentgenol. 2017;209:289–303. https://doi.org/10.2214/AJR.17.18301.CrossRefPubMed

22.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

23.

Alberts I, Sachpekidis C, Prenosil G, Viscione M, Bohn KP, Mingels C, et al. Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. Ann Nucl Med. 2021;35:485–92. https://doi.org/10.1007/s12149-021-01588-6.CrossRefPubMedPubMedCentral

24.

Meerwein CM, Queiroz M, Kollias S, Hullner M, Veit-Haibach P, Huber GF. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. Swiss Med Wkly. 2015;145:w14116. https://doi.org/10.4414/smw.2015.14116.CrossRefPubMed

25.

Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research, 3rd ed. Chapman and Hall/CRC. 2017. https://doi.org/10.1201/9781315183084.

26.

Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2021;48:1966–75. https://doi.org/10.1007/s00259-020-05091-4.CrossRefPubMed

27.

Alberts I, Sari H, Mingels C, et al. Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imaging. 2023;23:28. https://doi.org/10.1186/s40644-023-00540-3.CrossRefPubMedPubMedCentral

28.

Daube-Witherspoon M, Pantel A, Pryma D, Karp J. Total-body PET: a new paradigm for molecular imaging. Br J Radiol. 2022:20220357. https://doi.org/10.1259/bjr.20220357.

29.

Fuentes-Ocampo F, Lopez-Mora DA, Flotats A, Paillahueque G, Camacho V, Duch J, et al. Digital vs. analog PET/CT: intra-subject comparison of the SUVmax in target lesions and reference regions. Eur J Nucl Med Mol Imaging. 2019;46:1745–50. https://doi.org/10.1007/s00259-018-4256-0.CrossRefPubMed

30.

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345–8. https://doi.org/10.1007/s002590050593.CrossRefPubMed

31.

Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S, et al. The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47:642–51. https://doi.org/10.1007/s00259-019-04552-9.CrossRefPubMed

32.

Pietrzak AK, Kazmierska J, Marszalek A, Golusinski P, Heydrych A, Wiechec K, et al. Dual-time-point PET/CT study protocol can improve the larynx cancer diagnosis. Rep Pract Oncol Radiother. 2020;25:533–8. https://doi.org/10.1016/j.rpor.2020.04.013.CrossRefPubMedPubMedCentral

33.

Mao W, Zhou J, Qiu L, Yin H, Tan H, Shi H. The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases. Abdom Radiol (NY). 2020;45:1075–81. https://doi.org/10.1007/s00261-019-02396-3.CrossRefPubMed

34.

Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [(68)Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12102788.

35.

Viswanath V, Sari H, Pantel AR, Conti M, Daube-Witherspoon ME, Mingels C, et al. Abbreviated scan protocols to capture (18)F-FDG kinetics for long axial FOV PET scanners. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05747-3.CrossRefPubMedPubMedCentral

36.

Wu Y, Feng T, Zhao Y, Xu T, Fu F, Huang Z, et al. Whole-body parametric imaging of (18)F-FDG PET using uEXPLORER with reduced scanning time. J Nucl Med. 2022;63:622–8. https://doi.org/10.2967/jnumed.120.261651.CrossRefPubMedPubMedCentral

Title: The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation
Authors: Riccardo Mei
Thomas Pyka
Hasan Sari
Stefano Fanti
Ali Afshar-Oromieh
Roland Giger
Federico Caobelli
Axel Rominger
Ian Alberts
Publication date: 14-12-2023
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2024
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06516-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Impact of patient motion on parametric PET imaging

Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [18F]FDG tumor kinetic metrics

Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners

FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis

Advances in targeted alpha therapy of cancer

Correction to: Theranostic role of 89Zr‑ and 177Lu‑labeled aflibercept in breast cancer